IL240963A - Breathing agglomerates of airborne carrier particles and minimized drugs - Google Patents

Breathing agglomerates of airborne carrier particles and minimized drugs

Info

Publication number
IL240963A
IL240963A IL240963A IL24096315A IL240963A IL 240963 A IL240963 A IL 240963A IL 240963 A IL240963 A IL 240963A IL 24096315 A IL24096315 A IL 24096315A IL 240963 A IL240963 A IL 240963A
Authority
IL
Israel
Prior art keywords
carrier particles
porous carrier
micronized drug
respirable agglomerates
respirable
Prior art date
Application number
IL240963A
Other languages
English (en)
Hebrew (he)
Other versions
IL240963A0 (en
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL240963A0 publication Critical patent/IL240963A0/en
Publication of IL240963A publication Critical patent/IL240963A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL240963A 2013-03-14 2015-08-31 Breathing agglomerates of airborne carrier particles and minimized drugs IL240963A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784842P 2013-03-14 2013-03-14
PCT/IB2014/059739 WO2014141135A1 (en) 2013-03-14 2014-03-13 Respirable agglomerates of porous carrier particles and micronized drug

Publications (2)

Publication Number Publication Date
IL240963A0 IL240963A0 (en) 2015-11-30
IL240963A true IL240963A (en) 2017-05-29

Family

ID=50478894

Family Applications (1)

Application Number Title Priority Date Filing Date
IL240963A IL240963A (en) 2013-03-14 2015-08-31 Breathing agglomerates of airborne carrier particles and minimized drugs

Country Status (22)

Country Link
US (2) US9452139B2 (enExample)
EP (1) EP2968570A1 (enExample)
JP (1) JP6374414B2 (enExample)
KR (1) KR20150129716A (enExample)
CN (1) CN105188757B (enExample)
AU (2) AU2014229265A1 (enExample)
BR (1) BR112015021814A2 (enExample)
CA (1) CA2905615A1 (enExample)
CL (1) CL2015002632A1 (enExample)
EA (1) EA201591729A1 (enExample)
GT (1) GT201500295A (enExample)
HK (1) HK1212616A1 (enExample)
IL (1) IL240963A (enExample)
MA (1) MA38397A1 (enExample)
MX (1) MX2015012814A (enExample)
PE (1) PE20151655A1 (enExample)
PH (1) PH12015501882A1 (enExample)
SA (1) SA515361055B1 (enExample)
SG (1) SG11201506397QA (enExample)
TN (1) TN2015000395A1 (enExample)
WO (1) WO2014141135A1 (enExample)
ZA (1) ZA201505768B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明(cyclopamine)類似物類
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
RU2745977C2 (ru) 2010-04-22 2021-04-05 Вертекс Фармасьютикалз Инкорпорейтед Способ получения циклоалкилкарбоксамидо-индольных соединений
AU2014210942A1 (en) * 2013-01-31 2015-08-20 Prosonix Limited Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy
US9452139B2 (en) * 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
EP3122331A1 (en) * 2014-03-27 2017-02-01 Novartis AG Spray-dried solid-in-oil-in-water dispersions for inhalation of active pharmaceutical ingredients
SG10201913575VA (en) 2014-04-15 2020-02-27 Vertex Pharma Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
EP3204358B1 (en) 2014-10-07 2018-09-19 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
WO2016142708A2 (en) * 2015-03-10 2016-09-15 Cipla Limited Pharmaceutical composition
US10423736B2 (en) * 2015-08-28 2019-09-24 University Of British Columbia Methods and systems for simulating hydrodynamics in gas-solid fluidized beds
EP3335699A1 (en) 2016-12-15 2018-06-20 H e x a l Aktiengesellschaft Selexipag formulation in liquisolid system
CN106943350A (zh) * 2017-03-14 2017-07-14 上海现代药物制剂工程研究中心有限公司 含毒蕈碱受体拮抗剂和β2受体激动剂的气雾剂及制备方法
WO2019060595A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
US20200324064A1 (en) * 2019-04-10 2020-10-15 Cai Gu Huang Inhalation Device for Administering Powdered Pharmaceutical Composition
WO2020247376A1 (en) * 2019-06-03 2020-12-10 Cai Gu Huang Inhalable formulation of a solution containing indacaterol maleate and glycopyrronium bromide
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
EP4013245A1 (en) * 2019-08-15 2022-06-22 Abbott Laboratories Nutritional powder manufacturing process using micronization, and powder composition
CA3175211A1 (en) * 2020-04-13 2021-10-21 Matthias Emanuel LIECHTI Lsd dose identification
CN114344285B (zh) * 2020-10-14 2023-11-14 江苏恒瑞医药股份有限公司 改良的可吸入团聚物
CN116546980A (zh) * 2020-12-11 2023-08-04 江苏恒瑞医药股份有限公司 用于肺部递送的药物组合物
CN113318097A (zh) * 2021-04-29 2021-08-31 珠海瑞思普利医药科技有限公司 一种抗特发性肺纤维化的粉雾剂及制备方法
EP4329759A4 (en) 2021-04-30 2025-07-16 Mind Medicine Inc CRYSTALLINE FORMS OF LSD SALTS
EP4387624A4 (en) 2021-08-19 2025-07-30 Mind Medicine Inc Immediate Release Formulations of Diethylamide of D-Lysergic Acid for Therapeutical Applications
CN116785239A (zh) * 2022-03-17 2023-09-22 上海惠永药物研究有限公司 喷雾冷冻干燥制备微球的方法
CN116785246A (zh) * 2022-03-17 2023-09-22 上海惠永药物研究有限公司 一种药物微球及含其的气雾剂
CN117357485B (zh) * 2023-11-01 2024-09-24 山东京卫制药有限公司 一种改良的可吸入的载体颗粒及应用
WO2025256638A1 (zh) * 2024-06-14 2025-12-18 上海济昀生物科技有限公司 一种混悬型三联吸入气雾剂组合物及其制备方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
IT1016489B (it) 1974-03-18 1977-05-30 Isf Spa Inalatore
ATE8790T1 (de) 1981-02-02 1984-08-15 Schering Corporation Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
ATE137675T1 (de) 1991-06-26 1996-05-15 Schering Corp Inhalator für medikamente in pulverform
PL173090B1 (pl) 1992-12-18 1998-01-30 Schering Corp Inhalator do sproszkowanych lekarstw
US6794357B1 (en) * 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
JP3706136B2 (ja) 1994-09-21 2005-10-12 ネクター セラピューティクス 乾燥粉末薬剤の分散装置及び方法
CA2241880A1 (en) 1996-01-03 1997-07-17 Glaxo Group Limited Inhalation device
SK287878B6 (sk) 1996-02-21 2012-02-03 Schering Corporation Powdered medication inhaler
US6613795B2 (en) 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
DK0937041T3 (da) 1996-11-11 2003-08-11 Christian R Noe Anvendelse af et farmaceutisk egnet salt af (3R,2'R)-3-[(cyclopentil-hydroxyphenylacetyl)oxyl]-1,1-dimethyl-pyrrolidinium til fremstilling af et lægemiddel
US6010935A (en) 1997-08-21 2000-01-04 Micron Technology, Inc. Self aligned contacts
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
UA73924C2 (en) 1998-10-09 2005-10-17 Nektar Therapeutics Device for delivering active agent formulation to lungs of human patient
CA2347856C (en) 1998-11-13 2009-02-17 Jagotec Ag Dry powder for inhalation
US20070212422A1 (en) 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
MXPA01012246A (es) 1999-05-28 2002-08-12 Inhale Therapeutic Syst Aparato y metodo para distribuir una cantidad medida de medicamento en aerosol.
US6679256B2 (en) 1999-12-17 2004-01-20 Nektar Therapeutics Systems and methods for extracting powders from receptacles
US7069929B2 (en) 2000-02-01 2006-07-04 Quadrant Technologies Limited Dry powder inhaler
WO2001085136A2 (en) 2000-05-10 2001-11-15 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
AU2003287132B2 (en) 2002-12-13 2009-03-12 Adagit Pharmaceutical porous particles
DK1610850T3 (da) 2003-04-09 2012-06-25 Novartis Ag Aerosolapparat med luftindløbsskærm
GB0317374D0 (en) 2003-07-24 2003-08-27 Glaxo Group Ltd Medicament dispenser
GB2407042B (en) 2003-10-17 2007-10-24 Vectura Ltd Inhaler
CA2554136C (en) 2004-02-24 2013-05-28 Microdose Technologies, Inc. Synthetic jet based medicament delivery method and apparatus
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
GB0413960D0 (en) 2004-06-22 2004-07-28 Novartis Ag Organic compounds
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
BRPI0713951B8 (pt) 2006-06-30 2021-05-25 Novartis Ag derivados de quinazolina, e composição farmacêutica
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
RU2463085C2 (ru) 2006-10-25 2012-10-10 Новартис Аг Аппарат для распыления порошка, способ его изготовления и применения и его компоненты
JP5727927B2 (ja) 2008-05-15 2015-06-03 ノバルティス アーゲー フルオロキノロンの肺送達
PL2417106T3 (pl) 2009-04-09 2017-05-31 Novartis Ag Sposób wytwarzania soli pirolidyniowych
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
BR112012024059B1 (pt) 2010-04-01 2021-06-01 Chiesi Farmaceutici S.P.A. Processo de preparo de um excipiente para composições farmacêuticas em pó para inalação, partículas carreadoras para uma formulação farmacêutica de pó seco, composição farmacêutica em forma de pó seco para inalação e inalador de pó seco
JOP20120023B1 (ar) * 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
US9452139B2 (en) * 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug

Also Published As

Publication number Publication date
EP2968570A1 (en) 2016-01-20
US20140302147A1 (en) 2014-10-09
EA201591729A1 (ru) 2016-05-31
SA515361055B1 (ar) 2016-11-13
AU2014229265A1 (en) 2015-09-03
US20160354388A1 (en) 2016-12-08
CN105188757B (zh) 2019-04-30
WO2014141135A1 (en) 2014-09-18
PE20151655A1 (es) 2015-11-26
JP2016512494A (ja) 2016-04-28
HK1212616A1 (zh) 2016-06-17
SG11201506397QA (en) 2015-09-29
CL2015002632A1 (es) 2016-03-28
KR20150129716A (ko) 2015-11-20
MA38397A1 (fr) 2018-01-31
US9452139B2 (en) 2016-09-27
GT201500295A (es) 2017-09-28
CN105188757A (zh) 2015-12-23
TN2015000395A1 (en) 2017-01-03
JP6374414B2 (ja) 2018-08-15
MX2015012814A (es) 2016-02-03
IL240963A0 (en) 2015-11-30
AU2017203258B2 (en) 2019-06-20
BR112015021814A2 (pt) 2017-07-18
CA2905615A1 (en) 2014-09-18
PH12015501882A1 (en) 2015-12-07
ZA201505768B (en) 2017-03-29
AU2017203258A1 (en) 2017-06-08
US9744178B2 (en) 2017-08-29

Similar Documents

Publication Publication Date Title
IL240963A (en) Breathing agglomerates of airborne carrier particles and minimized drugs
IL236666B (en) Systems and methods for delivering a drug as a dry powder
IL240291A0 (en) History of pyridazinone and pharmaceutical preparations containing them
IL245053A0 (en) A system for creating a spray for creating and controlling the amount of nicotine salt particles
EP3052551A4 (en) Benefit agent containing delivery particle
SG11201600707QA (en) Substituted aminopyrimidine compounds and methods of use
EP3063982A4 (en) User equipment and methods of bearer operation for carrier aggregation
SG11201510179PA (en) Amino-triazine derivatives and pharmaceutical composition containing said derivatives
SG11201505411RA (en) Microdevices for separation of non-spherical particles and applications thereof
PL2976072T3 (pl) Drobne cząstki epinefryny i sposoby ich stosowania do leczenia chorób reagujących na epinefrynę
PT3613421T (pt) Ácido acetilsalicílico para reduzir o risco de um evento tromboembólico
EP2964261A4 (en) STABILIZATION OF MOISTURE-SENSITIVE DRUGS
IL244496A0 (en) Synthesis and particle engineering of co-crystals
PT3470074T (pt) Probióticos
EP3006106A4 (en) Catalyst particles, loaded catalyst particles, and use of same
IL240505A0 (en) Accumulations of lanthanides and methods for their use
GB201806558D0 (en) Superfically porous particles with precisely controlled particle density and methods of preparation and use thereof
IL240292B (en) History of quinazoline and pharmaceutical preparations containing them
IL276838B (en) Oral formulation and suspension of an oncology drug
ZA201507706B (en) Inhalable pharmaceutical compositions and the inhaler devices containing them
IL241070A0 (en) Powder particles with additional coating
GB201307082D0 (en) Pharmaceutical composition comprising 15-HETrE and methods of using the same
GB201307659D0 (en) Preparation of drug particles by micronisation
GB201415815D0 (en) Size reduction device and method for the size reduction of solid particles
AU2013205497B2 (en) Dry powder inhaler and methods of use

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed